ATAI:NASDAQ
AtaiBeckley Inc
$4.06
arrow_downward
-0.25%(-0.010) 1D
$4.02
arrow_downward
-0.99% (-0.040)bedtimeAfter hours
Closed: Jun 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ATAI...
Open
$4.16
High
$4.22
Low
$4.00
Mkt. cap
1.49B
Avg. vol.
4.96M
Volume
6.62M
52-wk high
$6.72
52-wk low
$2.00
EPS
-$2.23
Beta
1.60
Shares outstanding
368.17M
No. of employees
99
Open
$4.16
High
$4.22
Low
$4.00
Mkt. cap
1.49B
Avg. vol.
4.96M
Volume
6.62M
52-wk high
$6.72
52-wk low
$2.00
EPS
-$2.23
Beta
1.60
Shares outstanding
368.17M
No. of employees
99
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to ATAI in the past 3 months
Strong Buy
Buy
9
Hold
0
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ATAI in the last 3 months.
Highest
Current $4.06
$25.00 (+515.76%)
Average
$16.13 (+297.29%)
Lowest
$12.00 (+195.57%)
News stories
From sources across the web
Yahoo Finance
·
2 days ago
Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
Profile
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was formed in November 2025 through the merger of atai Life Sciences, founded in 2018, and Beckley Psytech, founded in 2019.
In December 2025, the company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
The company's pharmaceutical candidates include mebufotenin, dimethyltryptamine, and-midomafetamine. Wikipedia
About AtaiBeckley Inc
CEOFlorian Brand
Employees99
Founded2018
Headquarters-
SectorPharmaceutical industry
Websiteataibeckley.com
AI content may include mistakes. Learn more